Asensus Surgical(US:ASXC)2021-11-03 23:29Financial Data and Key Metrics Changes - For Q3 2021, the company reported revenue of $2.6 million, a significant increase from $0.8 million in Q3 2020, representing a year-over-year growth of 225% [10] - Total operating expenses for Q3 2021 were $16.7 million, up from $14.6 million in Q3 2020 [10] - The net loss attributable to common stockholders was $16.1 million or $0.07 per share, compared to a net loss of $15.1 million or $0.15 per share in the same quarter last year [10] - The adjusted net loss attributable to common stockholders was $14.3 million or $0.06 per share, compared to an adjusted net loss of $11.9 million or $0.12 per share in Q3 2020 [11] - As of September 30, 2021, the company had cash and investments of approximately $147.9 million and working capital of $125.4 million [11] Business Line Data and Key Metrics Changes - Revenue in Q3 2021 included $1.4 million in system revenue, $0.8 million in instruments and accessories, and $0.4 million in services [10] - The company signed lease agreements with 3 hospitals and sold 1 system, bringing the total number of new Senhance program initiations in 2021 to 6 [9] Market Data and Key Metrics Changes - Total procedure volume increased over 47% year-over-year and grew over 5% compared to Q2 2021, with year-to-date procedure volumes exceeding 1,500 [16] - Procedure volumes in the EMEA region grew by 71%, while the U.S. saw a 41% increase; however, volumes in Asia remained flat due to COVID-related challenges [16] Company Strategy and Development Direction - The company aims to continue market development for the Senhance system and expand its portfolio while advancing technology [12] - Japan is identified as a key geography for growth due to a favorable landscape for laparoscopic surgery and extensive reimbursement coverage [14] - The company plans to invest in Japan to grow its footprint, including establishing a training center [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong procedure volume growth and the acceleration of new system installations despite COVID-19 disruptions [22] - The company expects to meet its goal of 10 to 12 new program initiations by the end of 2021 and anticipates continued growth in procedure volumes [23] Other Important Information - The company received FDA 510(k) clearance for both 5-millimeter articulating instruments and expanded capabilities of the Intelligent Surgical Unit (ISU) [18] - Supply chain issues related to one component of the ISU may delay broader application, but the company expects to ramp up rollout once resolved [20] Q&A Session Summary Question: Clarification on top-line revenue and system bookings - Management confirmed that the $1.4 million in system bookings included both a capital purchase and lease revenues [24] Question: Factors contributing to the increase in procedure volumes - Management noted that growth was primarily driven by the EMEA region and the U.S., with a steady pace of growth quarter-over-quarter [26][27] Question: Benefits of portfolio enhancements with ISU and articulating arms - Management emphasized that the goal is to reduce variability in surgery and improve outcomes, rather than just adding features [29][30] Question: Future resource allocation in Japan - Management indicated that current resources can support more systems in Japan, and they plan to invest further to enhance the surgeon experience [32]